This Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials

What happened

Cambridge startup Qureight raised $20 million in a Series B funding round led by Molten Ventures. The company develops AI imaging tools for clinical trials focused on lung and heart health. Rather than building separate AI models for each disease, Qureight is creating a single “foundation model” that covers the entire chest area. This model can then be adapted for specific conditions, speeding up imaging analysis across multiple clinical trials.

Why it matters

Most AI imaging startups create disease-specific models, which slows development and raises costs, since each new disease requires new training and validation. Qureight’s approach tackles that by building a comprehensive model from one source. This reduces repetitive work and could accelerate drug trials by providing faster, more consistent imaging insights across different conditions in the lung and heart. For drug developers, this promises more efficient trial imaging workflows, lower AI development costs, and potentially faster patient recruitment and outcome assessment.

What to watch next

The key indicator will be whether Qureight can prove this foundation model adapts effectively to diverse clinical trial needs without losing accuracy. Its success would pressure competitors relying on siloed models. Investors and pharma partners will watch for trial outcomes that demonstrate reduced timelines and costs. Expansion into other imaging domains beyond the chest would also signal scalability. Finally, regulatory acceptance of foundation models in clinical settings will determine how quickly this approach reshapes trial workflows.

AI Quick Briefs Editorial Desk